Welcome, Guest. Please login or register.
April 28, 2024, 11:43:58 am

Login with username, password and session length


Members
Stats
  • Total Posts: 773307
  • Total Topics: 66349
  • Online Today: 662
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 618
Total: 619

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Evidence for link between leaky gut and autoantibody production in HIV patients  (Read 2165 times)

0 Members and 1 Guest are viewing this topic.

Offline GoForIt

  • Member
  • Posts: 214
Full article:  https://medicalxpress.com/news/2019-04-evidence-link-leaky-gut-autoantibody.html

Human immunodeficiency virus, or HIV, attacks the immune system, making affected individuals more susceptible to infections. When patients with HIV are treated with antiretroviral therapy (ART), their immune system can recover, but some of them produce self-destructive proteins, or autoantibodies.

Instead of attacking foreign invaders such as bacteria or viruses, some autoantibodies attack the body's own cells. This is known as autoimmunity. We all produce low levels of autoantibodies. However, when they are produced persistently at high levels, autoimmunity may occur.

In an article in Microbiome, Wei Jiang, M.D., associate professor in the Department of Microbiology and Immunology at the Medical University of South Carolina (MUSC), and her team report that HIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (Staphylococcus aureus) products in their blood.

The MUSC study compared autoantibody production in HIV-positive patients and healthy individuals before and after receiving a seasonal flu vaccine. Patients provided blood samples before vaccination and one and two weeks after. The blood samples were tested using a 125-autoantibody array panel.

The autoimmune response in the HIV-positive patients was linked to the presence of Staphylococcus aureus products in the blood. This is the same bacteria responsible for skin staph infections. Some HIV-positive patients have a higher baseline level of these bacterial products in their system. The team examined other strains of bacteria but linked only Staphylococcus aureus to autoantibody production in HIV-positive individuals.

A "leaky gut" could explain the increased level of Staphylococcus products in the blood of HIV-positive patients.

In patients with "leaky gut," the intestinal lining is weakened, enabling bacteria and toxic products in the gut to enter the bloodstream, where they become vulnerable to the immune system. The immune system's attacks on these bacteria could also injure the body's own tissues.

A "leaky gut" is associated with persistent inflammation and several chronic illnesses, including HIV, irritable bowel syndrome, celiac disease, and type 1 diabetes.

To verify their findings, Jiang and her team injected heat-killed Staphylococcus bacteria into healthy mice and found that they did in fact stimulate autoantibody production.

"We used animals to verify what we found in humans," explains Jiang. "We saw that the level of Staphylococcus product was correlated with autoantibody production in HIV patients, and we hypothesized that these bacteria induced autoantibodies, so we tested our hypothesis in mice."

The mouse studies were supported by voucher funding from the South Carolina Clinical & Translational Research (SCTR) Institute, an NIH-funded Clinical and Translational Science Awards hub at MUSC.

The ability to further explore clinical findings in an animal model was crucial to this study. The mouse study showed that injection of Staphylococcus bacteria stimulates autoantibody production.

"We are now studying which Staphylococcus products are active in autoantibody production in mice," says Jiang. "It may be possible to design an inhibitor to block these bacteria from activating the immune cells."

Going forward, Jiang and her team hope to design a drug that inhibits Staphylococcus to help prevent autoimmunity in HIV-positive patients receiving ART.
08/09/2013  Diagnosed WB positive
08/20/2013  CD4-506(28%)  VL-10,800
09/12/2013  CD4-391(28%)  VL-14,900
09/17/2013  Start ART (Truvada + Tivicay)
10/11/2013  CD4-377(26%)  VL-UD
12/20/2013  CD4-590(??%)  VL-UD
03/18/2014  CD4-660(29%)  VL-UD
07/22/2014  CD4-613(29%)  VL-UD
08/01/2014   Start Phase 3 TAF (Truvada 2.0) Clinical Trial (TAF + Tivicay)
10/09/2014  CD4-498(29.5%) VL-UD
11/06/2014  CD4-600(30.2%) VL-UD
01/30/2015  CD4-529(31.3%) VL-UD
07/25/2015  CD4-742(36.5%) VL-UD
10/06/2015  CD4-765(28.9%) VL-UD
01/05/2016  CD4-907(33.1%) VL-UD
03/24/2016  CD4-770(33.5%) VL-UD
06/20/2016  CD4-850(35.4%) VL-UD

Dr. Mark Wainberg on Dolutegravir:
Video 1: https://youtu.be/wCXOgLJqJAY
Video 2: https://youtu.be/DKiaD7fHO-s

Offline tryingtostay

  • Member
  • Posts: 591
Good to see this.

Thanks for the post

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.